Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD Leuven, BELGIUM - May 6, 2024 - 6:00 PM CET, Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical ...
Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD Leuven, BELGIUM – – 6:00 PM CET, Oxurion ...
Targeting a major pharmaceutical market in retinal diseases, EyePoint Pharmaceuticals has revealed that its lead drug ...
EyePoint (EYPT) stock tumbled nearly 30% in premarket trading Monday after the company said a Phase 2 study for its eye drug ...
Shares of EyePoint Pharmaceuticals dropped nearly 30% premarket on Monday after the company said its experimental eye disease ...
Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month visual acuity results from patients ...
The DISCOVER Phase 1/2a trial is an open-label, single ascending dose, 9-month study that will evaluate the safety and bioactivity of AXT107 ...
BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company ...
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the tmeline for ...
When Lynn Olson was invited to exhibit some of her paintings in “Sight Beyond Limits,” she immediately came on board. The ...
Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia GlobeNewswire May 06 ...
Doug Hepner, a 95-year-old veteran, can't see the pins very well, his delivery has slowed and his average has dropped. But he ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results